Kenya set to receive injectable HIV preventive drug
Health & Science
By
Mercy Kahenda
| Jul 15, 2025
Kenya is set to receive Lenacapavir, a groundbreaking HIV preventive drug that will be administered as an injection just twice a year.
This makes it the first long-acting injectable form of pre-exposure prophylaxis (PrEP), offering an alternative to the daily oral pills currently used for HIV prevention.
"The Ministry of Health through the Division of National AIDS and STI Control Programme (NASCOP), in collaboration with various partners is working to ensure avaiability of the innovative product for Kenyans by January 2026," NASCOP has announced.
READ MORE
Ethical tax compliance must be rooted in integrity above all else
Why manufacturers are clashing with State standards levy
Kenya and Sweden agree new pact to reduce Sh72b food losses
The real truth about livestock feed additives
Tourism week ends with calls to revise park fees
Helb CEO Geoffrey Monari feted for financial governance
Christmas comes early for borrowers as banks cut loan rates
Tanzanian firm Amsons eyes Kenya's renewable energy sector
AfDB, KCB in Sh19b deal to boost economy
Developers turn to community-first model as Africa rewrites tech rules
Clinical data shows the drug has up to 99 percent efficacy in preventing HIV transmission.
“Lenacapavir is highly effective and long-lasting," added NASCOP.
The injection is administered under the skin in the abdominal area (stomach) by a healthcare provider and is designed to be discreet, convenient, and stigma-free.
Kenya is expected to receive the drug with procurement supported by the Global Fund and other partners.
The rollout will be coordinated by the Ministry of Health through NASCOP, in collaboration with partner organisations.
“This is a major milestone in our efforts to end HIV/AIDS by 2030,” NASCOP noted.
The official launch of Lenacapavir was announced following an agreement signed between the Global Fund and Gilead Sciences.
Alongside Kenya, other high HIV burden countries set to benefit from the new injectable PrEP include Botswana, Eswatini, Ethiopia, Lesotho, Malawi, Mozambique, Nigeria, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe.